Unibest
← Back to patent-cliff list

Istaroxime

Tier C — Watch / trade

Istaroxime

Sigma-Tau Spa
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets：Na+/K+ ATPase, ATP2A2

Indications (approved)：Cardiogenic shock, Heart failure, Acute decompensated heart failure

Regional status

US
Phase II
2020-09-28
EU
Phase II
2013-09-24
China
No progress
2015-12-01
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 9 · Total yield 100 mg
ISTA-00153-43-0ISTA-00242151-23-5ISTA-00342151-21-3ISTA-004203738-08-3ISTA-00568292-64-8ISTA-006—ISTA-007304-91-6ISTA-008—ISTA-00949644-02-2ISTA-01037866-45-8ISTA-011203737-83-1API · Istaroxime
CodeCAS No.Intermediate
ISTA-00153-43-0(3S,8R,9S,10R,13S,14S)-3-hydroxy-10,13-dimethyl-3,4,7,8,9,10,11,12,13,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17(2H)-one
ISTA-00242151-23-5(3S,8R,9S,10R,13S,14S)-3-((tert-butyldimethylsilyl)oxy)-10,13-dimethyl-1,2,3,4,7,8,9,10,11,12,13,14,15,16-tetradecahydro-17H-cyclopenta[a]phenanthren-17-one
ISTA-00342151-21-3(3S,8R,9S,10R,13S,14S,17S)-3-((tert-butyldimethylsilyl)oxy)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-ol
ISTA-004203738-08-3(3S,5S,6S,8R,9S,10R,13S,14S,17S)-3-((tert-butyldimethylsilyl)oxy)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-6,17-diol
ISTA-00568292-64-8(3S,5S,6S,8R,9S,10R,13S,14S,17S)-3-((tert-butyldimethylsilyl)oxy)-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-6,17-diyl diacetate
ISTA-006-(3S,5S,6S,8R,9S,10R,13S,14S,17S)-3-hydroxy-10,13-dimethylhexadecahydro-1H-cyclopenta[a]phenanthrene-6,17-diyl diacetate
ISTA-007304-91-62-iodosylbenzoic acid
ISTA-008-(5S,6S,8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxohexadecahydro-1H-cyclopenta[a]phenanthrene-6,17-diyl diacetate
ISTA-00949644-02-2(5S,6S,8R,9S,10R,13S,14S,17S)-6,17-dihydroxy-10,13-dimethylhexadecahydro-3H-cyclopenta[a]phenanthren-3-one
ISTA-01037866-45-82-(aminooxy)ethanamine
ISTA-011203737-83-1(5S,6S,8R,9S,10R,13S,14S,17S,E)-6,17-dihydroxy-10,13-dimethylhexadecahydro-3H-cyclopenta[a]phenanthren-3-one O-(2-aminoethyl) oxime

Frequently asked questions

What are the approved indications of Istaroxime?

Approved indications include: Cardiogenic shock, Heart failure, Acute decompensated heart failure.

When does the Istaroxime patent expire?

No public expiry year is available for Istaroxime yet; this page updates once verified.

How many synthesis routes are recorded for Istaroxime?

1 synthesis routes are recorded; the shortest is 9 steps with 100 mg total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Istaroxime intermediates?

All intermediates in Istaroxime routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for Istaroxime intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-29